The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
复制标题
DOI：
10.4088/jcp.v58n1205
复制
发表时间：
1997-12-01
影响因子：
5.3
通讯作者：
Chouinard, G
中科院分区：
文献类型：
--
作者：
Marder, SR;Davis, JM;Chouinard, G
背景资料：在北美进行的两项双盲试验中，513名慢性精神分裂症患者接受了利培酮、氟哌啶醇或安慰剂治疗。在本研究中，合并数据从两个trials.Method：患者被随机分配到接受安慰剂，固定剂量的利培酮（2，6，10和16毫克/天），或20毫克/天的氟哌啶醇8周。对阳性和阴性症状量表（PANSS）进行因子分析，得出五个维度（阴性症状、阳性症状、混乱的思维、不受控制的敌意/兴奋和焦虑/抑郁），类似于PANSS数据的先前因子分析研究的五个维度。平均变化PANSS因子评分从基线至治疗第6周和第8周的（症状减轻）在接受6-16 mg/kg的患者中显著更高。与接受安慰剂或氟哌啶醇的患者相比，利培酮的优势是最大的阴性症状，不受控制的敌意/兴奋，焦虑/抑郁。即使在最低剂量（2 mg/天）下，利培酮在减少阴性症状方面也显著上级氟哌啶醇（p ≤ 0.05）。利培酮和氟哌啶醇之间的PANSS评分的结果的差异不相关的锥体外系symptoms.Conclusion：利培酮产生显着（p小于或等于.05）比氟哌啶醇在所有五个维度上的改善。阴性症状、敌意/兴奋和焦虑/抑郁的组间差异较大，表明利培酮和其他5-羟色胺/多巴胺拮抗剂与常规抗精神病药物的作用有质的不同。
Background: In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo. In the present study, combined data from the two trials were analyzed.Method: Patients were randomly assigned to receive placebo,fixed doses of risperidone (2, 6, 10, and 16 mg/day), or 20 mg/day of haloperidol for 8 weeks. Factor analysis of scores on the Positive and Negative Syndrome Scale (PANSS) produced five dimensions (negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, and anxiety/depression), similar to the five dimensions of previous factor-analytic studies of PANSS data.Results: Mean changes (symptom reductions) in PANSS factor scores from baseline to treatment Weeks 6 and 8 were significantly greater in patients receiving 6-16 mg/day of risperidone than in patients receiving placebo or haloperidol. The advantages of risperidone were greatest for negative symptoms, uncontrolled hostility/excitement, and anxiety/depression. Even at the lowest dose, 2 mg/day, risperidone was significantly (p less than or equal to .05) superior to haloperidol in reducing negative symptoms. The differences in outcomes between risperidone and haloperidol on PANSS scores were not related to extrapyramidal symptoms.Conclusion: Risperidone produced significantly (p less than or equal to .05) greater improvements than haloperidol on all five dimensions. The large between-group differences on negative symptoms, hostility/excitement, and anxiety/depression suggest that risperidone and other serotonin/dopamine antagonists have qualitatively different effects from those of conventional antipsychotic agents.